基于CE-MRI的影像组学预测HER2阳性非肿块强化乳腺癌新辅助化疗疗效
回顾性分析117例HER2阳性非肿块强化乳腺癌患者的CE-MRI影像组学特征,构建列线图模型预测新辅助化疗后病理完全缓解,训练集AUC 0.900,测试集AUC 0.810,决策曲线显示临床获益优于其他模型。
要点
- HER2阳性非肿块强化乳腺癌,CE-MRI影像组学列线图可术前预测新辅助化疗后pCR。
- CE-MRI显示节段性强化者较区域性或弥漫性强化者更易达到pCR。
- 训练集AUC 0.900,测试集AUC 0.810,模型校准良好。
核心结论
- 基于CE-MRI的影像组学列线图模型可用于术前预测HER2阳性非肿块强化乳腺癌患者新辅助化疗的疗效。
- CE-MRI显示节段性强化者较区域性或弥漫性强化者更可能达到pCR。
研究设计与样本
- 回顾性分析2012年1月至2019年12月117例HER2阳性非肿块强化乳腺癌患者,均接受CE-MRI检查。
- 以手术标本及腋窝淋巴结无浸润性肿瘤细胞定义为病理完全缓解(pCR)。
- 从原发肿瘤提取1130个影像组学特征,经mRMR和LASSO算法筛选出6个特征。
- 将rad-score与独立危险因素结合构建列线图模型,在训练集和测试集中验证。
关键影像表现/征象
- CE-MRI上非肿块强化分为节段性、区域性和弥漫性强化,节段性强化者更易达到pCR。
诊断标准与关键数值
- 训练集AUC 0.900,测试集AUC 0.810,模型校准良好。
- pCR组与非pCR组rad-score差异在训练集和测试集中均有统计学意义(p < 0.01)。
临床应用与阅片要点
- 对HER2阳性非肿块强化乳腺癌患者,可结合CE-MRI影像组学列线图术前评估新辅助化疗后pCR概率。
- 阅片时注意非肿块强化的分布模式(节段性、区域性、弥漫性),节段性强化提示pCR可能性更高。
局限性
- 回顾性研究,样本量117例,未报告多中心外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To establish and validate a radiomics nomogram based on contrast-enhanced (CE)-MRI for predicting the efficacy of neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2 (HER2)-positive breast cancer with non-mass enhancement (NME).
METHODS: A cohort comprising 117 HER2-positive breast cancer patients showing NME on CE-MRI between January 2012 and December 2019 were retrospectively analysed in our study. Patients were classified as pathological complete respone (pCR) according to surgical specimens and axillary lymph nodes without invasive tumour cells. Clinicopathological data were recorded, and images were assessed by two radiologists. A total of 1130 radiomics features were extracted from the primary tumour and six radiomics features were selected by the maximal relevance and minimal redundancy and least absolute shrinkage and selection operator algorithms. Univariate logistic regression was used to screen meaningful clinical and imaging features. The rad-score and independent risk factors were incorporated to build a nomogram model. Calibration and receiver operator characteristic curves were used to confirm the performance of the nomogram in the training and testing cohorts. The clinical usefulness of the nomogram was evaluated by decision curve analysis.
RESULTS: The difference in the rad-score between the pCR and non-pCR groups was significant in the training and testing cohorts (p < 0.01). The nomogram model showed good calibration and discrimination, with AUCs of 0.900 and 0.810 in the training and testing cohorts. Decision curve analysis indicated that the radiomics-based model was superior in terms of patient clinical benefit.
CONCLUSION: The MRI-based radiomics nomogram model could be used to pre-operatively predict the efficacy of NAC in HER2-positive breast cancer patients showing NME.
ADVANCES IN KNOWLEDGE: HER2-positive breast cancer showing segmental enhancement on CE-MRI was more likely to achieve pCR after NAC than regional enhancement and diffuse enhancement.The MRI-based radiomics nomogram model could be used to pre-operatively predict the efficacy of NAC in HER2-positive breast cancer that showed NME.
引用
- Li, Huang, Xiao, et al. Value of radiomics based on CE-MRI for predicting the efficacy of neoadjuvant chemotherapy in invasive breast cancer. Br J Radiol. 2022. PMID: 36005646. doi:10.1259/bjr.20220186
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。